1.
Carmody LC, Germain AR, VerPlank L, et al. Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells. J Biomol Screen. 2012;17(9):1204-10. doi:10.1177/1087057112458317.
1.
Duvall JR, Bedard L, Naylor-Olsen AM, et al. Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile. ACS Infect Dis. 2017;3(5):349-359. doi:10.1021/acsinfecdis.6b00206.
1.
Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009;23(18):2152-65. doi:10.1101/gad.1820109.
1.
Ng PY, Masse CE, Shaw JT. Cycloaddition reactions of imines with 3-thiosuccinic anhydrides: synthesis of the tricyclic core of martinellic acid. Org Lett. 2006;8(18):3999-4002. doi:10.1021/ol061473z.
1.
Germain AR, Carmody LC, Morgan B, et al. Identification of a selective small molecule inhibitor of breast cancer stem cells. Bioorg Med Chem Lett. 2012;22(10):3571-4. doi:10.1016/j.bmcl.2012.01.035.
1.
Yamamoto S, Wu Z, Russnes HG, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014;25(6):762-77. doi:10.1016/j.ccr.2014.04.024.
1.
Fischbach MA, Lai JR, Roche ED, Walsh CT, Liu DR. Directed evolution can rapidly improve the activity of chimeric assembly-line enzymes. Proc Natl Acad Sci U S A. 2007;104(29):11951-6. doi:10.1073/pnas.0705348104.